引入升级药敏图:一种为无应答患者经验性抗菌药物调整提供信息的简单工具
研究基于2017至2020年大多伦多地区6家医院6577例革兰阴性菌血症,构建12种常用抗菌药物的升级药敏图,计算对某一药物耐药时对其他11种药物的敏感概率,发现从头孢曲松升级至哌拉西林-他唑巴坦的覆盖概率较低,升级药敏图可指导无应答患者的经验性治疗调整。
要点
- 升级药敏图可量化对某药耐药后对其他药物的敏感概率,辅助无应答患者的经验性升级。
- 头孢曲松耐药菌株中,哌拉西林-他唑巴坦敏感率21.2%,低于多种其他药物。
- 升级药敏图在4个研究年度和6家医院间保持一致。
核心结论
- 升级药敏图可用于指导无应答患者的经验性治疗调整,避免在疑似革兰阴性菌血症中常见地从头孢曲松升级至哌拉西林-他唑巴坦的做法。
研究设计与样本
- 基于2017至2020年大多伦多地区6家医院6577例革兰阴性菌血症发作,为12种常用抗菌药物生成升级药敏图。
- 对某抗生素耐药的病原体,计算对另外11种药物各自的敏感概率;并按研究年度、医院、社区或医院获得及病原体类型进行亚组分析。
主要发现
- 6577例革兰阴性菌血症中,覆盖概率分别为氨苄西林31.8%、头孢唑林62.7%、头孢曲松67.1%、哌拉西林-他唑巴坦72.5%、头孢他啶74.1%、甲氧苄啶-磺胺甲噁唑74.4%、环丙沙星77.1%、妥布霉素88.3%、庆大霉素88.8%、厄他培南91.0%、阿米卡星97.5%、美罗培南98.2%。
- 头孢曲松耐药分离株中,哌拉西林-他唑巴坦敏感率21.2%,显著低于甲氧苄啶-磺胺甲噁唑54.2%(P < .0001)、环丙沙星63.0%(P < .0001)、厄他培南73.4%(P < .0001)、妥布霉素80.1%(P < .0001)、庆大霉素82.8%(P < .0001)、美罗培南94.3%(P < .0001)和阿米卡星97.1%(P < .0001)。
- 甲氧苄啶-磺胺甲噁唑在美罗培南升级药敏图中排名第二(49.6%),在阿米卡星升级药敏图中排名第一(86.0%)。
- 升级药敏图在4个研究年度和6家医院间保持一致。
关键数值与推荐
- 对头孢曲松耐药的革兰阴性菌血症分离株,哌拉西林-他唑巴坦敏感率21.2%,甲氧苄啶-磺胺甲噁唑54.2%,环丙沙星63.0%,厄他培南73.4%,妥布霉素80.1%,庆大霉素82.8%,美罗培南94.3%,阿米卡星97.1%。
- 在美罗培南升级药敏图中甲氧苄啶-磺胺甲噁唑敏感率49.6%,在阿米卡星升级药敏图中甲氧苄啶-磺胺甲噁唑敏感率86.0%。
临床怎么用
- 作者认为升级药敏图可提供重要信息,例如在疑似革兰阴性菌血症中避免常见地从头孢曲松升级至哌拉西林-他唑巴坦的做法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital antibiograms guide initial empiric antibiotic treatment selections, but do not directly inform escalation of treatment among nonresponding patients. METHODS: Using gram-negative bacteremia as an exemplar condition, we sought to introduce the concept of an escalation antibiogram. Among episodes of gram-negative bacteremia between 2017 and 2020 from 6 hospitals in the Greater Toronto Area, we generated escalation antibiograms for each of 12 commonly used agents. Among organisms resistant to that antibiotic, we calculated the likelihood of susceptibility to each of the other 11 agents. In subgroup analyses, we examined escalation antibiograms across study years, individual hospitals, community versus hospital onset, and pathogen type. RESULTS: Among 6577 gram-negative bacteremia episodes, the likelihood of coverage was ampicillin 31.8%, cefazolin 62.7%, ceftriaxone 67.1%, piperacillin-tazobactam 72.5%, ceftazidime 74.1%, trimethoprim-sulfamethoxazole 74.4%, ciprofloxacin 77.1%, tobramycin 88.3%, gentamicin 88.8%, ertapenem 91.0%, amikacin 97.5%, and meropenem 98.2%. The escalation antibiograms revealed marked shifts in likelihood of coverage by the remaining 11 agents. For example, among ceftriaxone-resistant isolates, piperacillin-tazobactam susceptibility (21.2%) was significantly lower than trimethoprim-sulfamethoxazole (54.2%, P < .0001), ciprofloxacin (63.0%, P < .0001), ertapenem (73.4%, P < .0001), tobramycin (80.1%, P < .0001), gentamicin (82.8%, P < .0001), meropenem (94.3%, P < .0001), and amikacin (97.1%, P < .0001). Trimethoprim-sulfamethoxazole was the second-ranked agent in the meropenem escalation antibiogram (49.6%) and first in the amikacin escalation antibiogram (86.0%). Escalation antibiograms were consistent across 4 study years and 6 hospitals. CONCLUSIONS: Escalation antibiograms can be generated to inform empiric treatment changes in nonresponding patients. These tools can yield important insights such as avoiding the common maneuver of escalating from ceftriaxone to piperacillin-tazobactam in suspected gram-negative bacteremia.
引用
- Teitelbaum D, Elligsen M, Katz K, et al. Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in the Nonresponding Patient. Clin Infect Dis. 2022. PMID: 35380628. doi:10.1093/cid/ciac256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。